Resistance to the BCL-XL degrader DT2216 in T-cell acute lymphoblastic leukemia is rare and correlates with decreased BCL-XL proteolysis

Kale J, Osterlund EJ, Andrews DW (2017) Bcl-2 family proteins: changing partners in the dance towards death. Cell Death Differ 25(1):65–80. https://doi.org/10.1038/cdd.2017.186

Article  CAS  PubMed  PubMed Central  Google Scholar 

Shamas-Din A, Kale J, Leber B, Andrews DW (2013) Mechanisms of action of bcl-2 family proteins. Cold Spring Harb Perspect Biol 5(4):a008714. https://doi.org/10.1101/cshperspect.a008714

Article  CAS  PubMed  PubMed Central  Google Scholar 

Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DC, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Elmore SW (2013) ABT-199, a potent and selective bcl-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202–208. https://doi.org/10.1038/nm.3048

Article  CAS  PubMed  Google Scholar 

Zhang X, Liu X, Zhou D, Zheng G (2020) Targeting anti-apoptotic BCL-2 family proteins for cancer treatment. Future Med Chem 12(7):563–565. https://doi.org/10.4155/fmc-2020-0004

Article  CAS  PubMed  Google Scholar 

Gandhi L, Camidge DR, Ribeiro de Oliveira M, Bonomi P, Gandara D, Khaira D, Hann CL, McKeegan EM, Litvinovich E, Hemken PM, Dive C, Enschede SH, Nolan C, Chiu YL, Busman T, Xiong H, Krivoshik AP, Humerickhouse R, Shapiro GI, Rudin CM (2011) Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29(7):909–16. https://doi.org/10.1200/JCO.2010.31.6208

Article  CAS  PubMed  PubMed Central  Google Scholar 

He Y, Khan S, Huo Z, Lv D, Zhang X, Liu X, Yuan Y, Hromas R, Xu M, Zheng G, Zhou D (2020) Proteolysis targeting chimeras (protacs) are emerging therapeutics for hematologic malignancies. J Hematol Oncol 13(1):103–127. https://doi.org/10.1186/s13045-020-00924-z

Article  PubMed  PubMed Central  Google Scholar 

He Y, Koch R, Budamagunta V, Zhang P, Zhang X, Khan S, Thummuri D, Ortiz YT, Zhang X, Lv D, Wiegand JS, Li W, Palmer AC, Zheng G, Weinstock DM, Zhou D (2020) DT2216—a bcl-xl-specific degrader is highly active against bcl-xl-dependent T cell lymphomas. J Hematol Oncol 13(1):95–108. https://doi.org/10.1186/s13045-020-00928-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khan S, Zhang X, Lv D, Zhang Q, Zhang P, Liu X, Thummuri D, Yuan Y, Wiegand J, Pei J, Zhang W, Sharma A, Mccurdy C, Kuruvilla V, Baran N, Ferrando A, Kim Y, Rogojina A, Zhou D (2019) A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity. Nat Med. https://doi.org/10.1038/s41591-019-0668-z

Article  PubMed  PubMed Central  Google Scholar 

Thummuri D, Khan S, Underwood PW, Zhang P, Wiegand J, Zhang X, Budamagunta V, Sobh A, Tagmount A, Loguinov A, Riner AN, Akki AS, Williamson E, Hromas R, Vulpe CD, Zheng G, Trevino JG, Zhou D (2022) Overcoming gemcitabine resistance in pancreatic cancer using the BCL-XL-specific degrader DT2216. Mol Cancer Ther 21(1):184–192. https://doi.org/10.1158/1535-7163.MCT-21-0474

Article  CAS  PubMed  Google Scholar 

Khan S, Wiegand J, Zhang P, Hu W, Thummuri D, Budamagunta V, Hua N, Jin L, Allegra CJ, Kopetz SE, Zajac-Kaye M, Kaye FJ, Zheng G, Zhou D (2022) BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers. J Hematol Oncol 15(1):23. https://doi.org/10.1186/s13045-022-01241-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Békés M, Langley DR, Crews CM (2022) PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov 21:181–200. https://doi.org/10.1038/s41573-021-00371-6

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gao H, Sun X, Rao Y (2020) PROTAC Technology: opportunities and challenges. ACS Med Chem Lett 11(30):237–240. https://doi.org/10.1021/acsmedchemlett.9b00597

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma A, Pena JC, Chang B, Margosian E, Davidson L, Alt FW, Thompson CB (1995) (1995) Bclx regulates the survival of double-positive thymocytes. Proc Natl Acad Sci USA 92(11):4763–4767. https://doi.org/10.1073/pnas.92.11.4763

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A (2014) Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov 4(9):1074–87. https://doi.org/10.1158/2159-8290.CD-14-0353

Article  CAS  PubMed  PubMed Central  Google Scholar 

Leung KT, Li KK, Sun SS, Chan PK, Ooi VE, Chiu LC (2008) Activation of the JNK pathway promotes phosphorylation and degradation of BimEL–a novel mechanism of chemoresistance in T-cell acute lymphoblastic leukemia. Carcinogenesis 29(3):544–51. https://doi.org/10.1093/carcin/bgm294

Article  CAS  PubMed  Google Scholar 

Kolb R, De U, Khan S et al (2021) Proteolysis-targeting chimera against BCL-XL destroys tumor-infiltrating regulatory T cells. Nat Commun 12:1281. https://doi.org/10.1038/s41467-021-21573-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Koch R, Christie AL, Crombie JL, Palmer AC, Plana D, Shigemori K, Morrow SN, Van Scoyk A, Wu W, Brem EA, Secrist JP, Drew L, Schuller AG, Cidado J, Letai A, Weinstock DM (2019) Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas. Blood 133(6):566–575. https://doi.org/10.1182/blood-2018-07-865527

Article  CAS  PubMed  PubMed Central  Google Scholar 

Follini E, Marchesini M, Roti G (2019) Strategies to overcome resistance mechanisms in T-cell acute lymphoblastic leukemia. Int J Mol Sci 20(12):3021. https://doi.org/10.3390/ijms20123021

Article  CAS  PubMed Central  Google Scholar 

Beesley A, Palmer ML, Ford J et al (2016) Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines. Br J Cancer 95:1537–1544. https://doi.org/10.1038/sj.bjc.6603447

Article  CAS  Google Scholar 

Raetz EA, Teachey DT (2016) T-cell acute lymphoblastic leukemia. Hematology 2016(1):580–588. https://doi.org/10.1182/asheducation-2016.1.580

Article  PubMed  PubMed Central  Google Scholar 

Goossens S, Radaelli E, Blanchet O et al (2015) ZEB2 drives immature T-cell lymphoblastic leukaemia development via enhanced tumour-initiating potential and IL-7 receptor signalling. Nat Commun 6:5794. https://doi.org/10.1038/ncomms6794

Article  CAS  PubMed  Google Scholar 

Lv D, Pal P, Liu X et al (2021) Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity. Nat Commun 12:6896. https://doi.org/10.1038/s41467-021-27210-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

留言 (0)

沒有登入
gif